Postoperative radiotherapy for stage IV breast cancer following primary tumor removal: Systematic review and meta-analysis

Review Article

De novo metastatic breast cancer (dnMBC) is diagnosed when breast cancer has spread at presentation and accounts for 5–10% of cases. The benefit of postoperative radiotherapy (PORT) after primary tumor surgery in this setting remains uncertain.
We conducted a review and meta-analysis of observational studies published between 2013 and 2024. Two databases (PubMed and Embase) were searched and the review followed PRISMA 2020 guidelines.

A phase II study of nivolumab plus metformin in pre-treated metastatic renal cell carcinoma patients: NivoMet TWINS-GU002 Study

Research Article

This study evaluates the activity of nivolumab plus metformin in pre-treated metastatic renal cell carcinoma (mRCC) patients.
The NivoMet TWINS-GU002 Study was a prospective, multicentre, single-arm, phase II trial conducted in pre-treated mRCC patients eligible for nivolumab and without diabetes mellitus. Patients received nivolumab (240 mg every two weeks) plus metformin (500 mg orally twice a day) until disease progression.